Anaesthesia for Parotid Surgery

Quick Answer

Exam Essentials - ANZCA Final Examination

Parotid Surgery Overview: Parotidectomy (partial or total) for benign/malignant tumours, chronic sialadenitis, or sialolithiasis. Facial nerve (CN VII) preservation is paramount; nerve monitoring commonly used [1-3].

Key Anaesthetic Considerations:

• Facial nerve monitoring: Electromyography (EMG) requires avoidance of long-acting NMBAs; maintain TOF count ≥1-2 or use short-acting agents; suxamethonium acceptable for RSI [4,5]
• Positioning: Supine with head-up 15-20°, head turned away from surgical side; shoulder support to expose neck [6,7]
• Duration: 2-4 hours (longer for total parotidectomy with neck dissection) [8,9]
• Blood loss: 100-300 mL typical; higher with malignancy/reoperations [10,11]
• Nerve identification: Facial nerve main trunk or peripheral branches must be identified and preserved [12,13]

Specific Concerns:

• Frey syndrome: Gustatory sweating due to aberrant nerve regeneration (10-50% incidence) [14,15]
• Facial weakness: Temporary (20-50%) or permanent (5-10%) depending on extent [16,17]
• Sialocele/fistula: Collection of saliva in wound (5-10%) [18,19]
• Great auricular nerve sacrifice: Numbness of earlobe and cheek (inevitable in most procedures) [20,21]

---

Indigenous Health Considerations

Aboriginal and Torres Strait Islander Populations

Epidemiology of Parotid Disease:

Parotid disease in Aboriginal and Torres Strait Islander populations reflects distinct patterns of risk factors and healthcare access:

• Chronic sialadenitis: Higher rates due to malnutrition, dehydration, and limited access to dental care [22,23]
• Sialolithiasis: Lower incidence than non-Indigenous populations [24]
• Neoplastic disease: Pleomorphic adenoma and Warthin tumour incidence similar; mucoepidermoid carcinoma rare [25]
• Benign lymphoepithelial lesions: Associated with HIV/AIDS (higher prevalence in some Indigenous communities) [26,27]

Risk Factors:

Barriers to Surgical Care:

1. Geographic isolation: Parotid surgery requires specialist ENT/head and neck surgical services concentrated in major cities
2. Delayed presentation: Patients may present with advanced disease due to limited primary care access
3. Cultural factors: Fear of surgery affecting facial expression/communication (critical for Aboriginal culture)
4. Communication: Complex surgical risks (facial paralysis, Frey syndrome) require careful explanation with interpreter support
5. Follow-up challenges: Facial nerve recovery monitoring requires multiple appointments [30,31]

Cultural Safety Considerations:

• Facial expression significance: In many Aboriginal cultures, facial expression is critical for communication; risk of facial paralysis particularly concerning
• Eye protection: If facial weakness, inability to close eye threatens corneal health; patient education critical
• Community concerns: Visible facial asymmetry may cause community concern; psychological support needed
• Aboriginal Health Worker involvement: Essential for preoperative education and postoperative support [32,33]

Postoperative Support:

• Physiotherapy: Limited access in remote areas for facial nerve rehabilitation
• Eye care: Corneal protection education if lagophthalmos; artificial tears availability
• Speech pathology: If facial weakness affects speech (articulation)
• Telehealth follow-up: Essential for remote patients to monitor nerve recovery [34,35]

Māori Populations (Aotearoa New Zealand)

Epidemiological Profile:

Māori experience similar patterns of parotid disease with some distinct considerations:

• Overall incidence: Similar to European New Zealanders for neoplastic disease
• Chronic sialadenitis: Higher rates in socioeconomically deprived communities
• Presentation: May present later due to access barriers [36,37]

Te Tiriti o Waitangi Considerations:

1. Equity of access: Timely referral pathways for Māori patients with parotid masses
2. Whānau-centred care: Family involvement in understanding surgical risks, particularly facial nerve paralysis
3. Māori Health Workers: Supporting patients through surgical pathway
4. Cultural communication: Appropriate discussion of facial appearance and communication concerns [38,39]

Postoperative Considerations:

• Facial nerve recovery monitoring: May require travel to main centres for specialist review
• Whānau support: Family may need to accompany patient for surgery in Auckland/Wellington/Christchurch
• Rehabilitation services: Physiotherapy and speech pathology access variable outside main centres
• Psychosocial support: Visible facial changes may impact cultural participation (mihi, whaikōrero) [40,41]

---

Epidemiology and Pathology

Parotid Tumour Statistics

Incidence:

• Annual incidence: 2-3 per 100,000 population [42]
• Age: Pleomorphic adenoma (30-50 years), Warthin tumour (60-70 years), malignancy (40-60 years) [43,44]
• Sex: Pleomorphic adenoma (F>M); Warthin tumour (M>>F, 5:1) [45]
• Bilateral: Warthin tumour (10% bilateral); lymphoma can be bilateral [46]

Tumour Classification:

Malignant Features:

• Pain
• Facial nerve palsy
• Rapid growth
• Skin fixation/ulceration
• Cervical lymphadenopathy
• Deep lobe involvement
• Age >60 years [50,51]

Non-Neoplastic Parotid Disease

Chronic Sialadenitis:

• Recurrent infections (often bacterial)
• Duct obstruction (stricture, stone)
• Autoimmune (Sjögren's syndrome)
• Treatment: Conservative → sialendoscopy → partial parotidectomy [52,53]

Sialolithiasis:

• Parotid stones less common than submandibular (10-20% vs 80-90%)
• Symptoms: Pain, swelling (especially with eating - "mealtime syndrome")
• Treatment: Sialogogues, massage, sialendoscopy, duct surgery [54,55]

Sjögren's Syndrome:

• Autoimmune destruction of salivary glands
• Dry eyes and mouth
• Parotid enlargement (bilateral, recurrent)
• Lymphoma risk (5-10% lifetime) [56,57]

---

Anatomy and Physiology Relevant to Anaesthesia

Parotid Gland Anatomy

Location and Relations:

• Largest salivary gland (25-30g)
• Occupies retromandibular fossa
• Anterior: Masseter muscle, mandible
• Posterior: Mastoid, SCM, ear
• Superior: Zygomatic arch, external auditory canal
• Medial: Styloid process, carotid sheath, pharyngeal wall
• Superficial: Skin, platysma, great auricular nerve [58,59]

Facial Nerve (CN VII) Anatomy:

Critical for Surgery:

• Exits stylomastoid foramen at anterior border of mastoid
• Enters parotid gland posteriorly
• Bifurcates into temporofacial and cervicofacial divisions within gland
• Further divides into 5 main branches: temporal, zygomatic, buccal, mandibular, cervical
• Course: Passes through parotid gland substance (gland bisected into superficial and deep lobes by nerve plane) [60,61]

Branch Functions:

Significance for Anaesthesia:

• Any facial nerve branch can be stimulated during dissection → EMG response
• Nerve monitoring requires avoidance of NMBAs during critical dissection phase
• Positioning must protect facial nerve from pressure/stretch injury

Other Important Anatomical Structures

Great Auricular Nerve (C2-C3):

• Ascends on SCM, crosses parotid superficially
• Innervates earlobe, angle of mandible, adjacent cheek skin
• Usually sacrificed in parotidectomy → numbness of earlobe and cheek [64,65]

Auriculotemporal Nerve (V3):

• Passes through parotid with superficial temporal vessels
• Carries parasympathetic fibres to parotid (secretomotor)
• Involved in Frey syndrome pathophysiology [66,67]

External Carotid Artery:

• Enters parotid posteriorly
• Gives off maxillary and superficial temporal arteries within gland
• Branches must be controlled during dissection [68,69]

Retromandibular Vein:

• Formed by superficial temporal and maxillary veins
• Exits parotid inferiorly, drains to external jugular and internal jugular
• Often ligated during parotidectomy [70,71]

Parotid Secretion Physiology

Salivary Composition:

• Serous secretion (watery, enzyme-rich)
• Amylase (starch digestion initiation)
• Lysozyme (antimicrobial)
• Lactoferrin, IgA, mucins
• Electrolytes (Na+, K+, Cl-, HCO3-) [72,73]

Regulation:

• Parasympathetic (primary): Auriculotemporal nerve (IX → otic ganglion → auriculotemporal) → secretion and vasodilation
• Sympathetic: Vasoconstriction (reduces secretion)
• Hormonal: Influenced by aldosterone (Na+ reabsorption)
• Reflex: Smell, taste, chewing stimulate secretion [74,75]

Clinical Relevance:

• Anticholinergics reduce salivation (useful preoperatively)
• Sialogogues (lemon, pilocarpine) stimulate secretion (used for sialolithiasis diagnosis/treatment)
• Frey syndrome: Aberrant regeneration of parasympathetic fibres to sweat glands → gustatory sweating [76,77]

---

Anaesthetic Management

Preoperative Assessment

Airway Evaluation:

• Usually straightforward unless very large tumour (rare)
• Previous surgery/radiation may alter anatomy
• Bilateral disease: Assess for potential airway compromise
• Mandibular involvement: Difficult intubation [78,79]

Specific Considerations:

Facial Nerve Function Assessment:

• Document voluntary movement: forehead wrinkle, eye closure, smile, lip pucker
• House-Brackmann grading if preoperative weakness
• Photograph for documentation
• Critical baseline for postoperative comparison [82,83]

Intraoperative Monitoring

Facial Nerve Monitoring (NIM):

Principles:

• Needle electrodes in facial muscles (frontalis, orbicularis oculi, orbicularis oris)
• Stimulator probe used by surgeon near nerve
• EMG response detected when nerve stimulated
• Audible alarm when nerve activated [84,85]

NMBA Management for Monitoring:

Alternatives to NMBAs during Monitoring:

• Remifentanil infusion (0.1-0.2 mcg/kg/min) + propofol TIVA
• Deep volatile anaesthesia (MAC 1.0-1.2)
• Goal: Immobility without neuromuscular blockade [88,89]

Sugammadex vs Neostigmine:

• Sugammadex: Rapid, complete reversal (recommended for nerve monitoring cases)
• Neostigmine: Slower, anticholinergic side effects; may have residual block
• Dose: Sugammadex 2-4 mg/kg depending on TOF count [90,91]

Airway Management

Intubation:

• Standard oral ETT (usually size 7.0-8.0)
• RAE tube (preformed) useful to keep anaesthetic tubing away from head
• Throat pack (if oral cavity accessed or to protect airway from blood)
• Secure ETT well (head turned during surgery) [92,93]

Positioning:

• Supine with head-up 15-20° (reduces bleeding)
• Head turned away from surgical side (45-90°)
• Shoulder support to extend neck and improve access
• Protect pressure points (occiput, heels)
• Ensure ETT not kinked with head rotation [94,95]

Temperature Management:

• Forced air warming (lower body)
• Warming blanket under patient
• Monitor temperature (prolonged procedures)

Haemodynamic Management

Goals:

• Controlled hypotension (MAP 60-70 mmHg) reduces bleeding [96,97]
• Adequate depth before surgical stimulation
• Smooth emergence to prevent coughing (risk of haematoma)

Technique:

• Propofol/remifentanil TIVA preferred (smooth, controllable)
• Volatile acceptable (avoid N2O if concurrent mastoid/ear surgery)
• Labetalol/esmolol for additional BP control if needed
• Phenylephrine if excessive hypotension [98,99]

Fluid Management:

• Restrictive strategy (airway accessible, but prevent haematoma)
• 1-2 mL/kg/hr balanced crystalloid
• Replace blood loss if >200 mL
• Blood transfusion rarely needed [100,101]

Emergence and Extubation

Criteria:

• Full reversal of NMBA (TOF ratio >0.9)
• Adequate oxygenation (SpO2 >95% on FiO2 0.4)
• Protective airway reflexes returned
• Haemostasis confirmed
• Deep emergence to prevent coughing [102,103]

Postoperative Airway Concerns:

• Haematoma formation (compress airway)
• Facial nerve weakness (airway protection if severe)
• Recurrent laryngeal nerve injury (if neck dissection)
• Obstructive sleep apnoea risk factors [104,105]

---

Complications and Management

Intraoperative Complications

Postoperative Complications

Facial Nerve Dysfunction:

Eye Protection (Critical):

• If lagophthalmos (inability to close eye):
  • Artificial tears every 1-2 hours
  • Eye ointment at night
  • Tape eyelids closed during sleep
  • Moisture chambers
  • Risk of corneal ulceration if not protected [111,112]

Frey Syndrome (Gustatory Sweating):

• Pathophysiology: Aberrant regeneration of parasympathetic secretomotor fibres to parotid → innervate sweat glands of overlying skin
• Incidence: 10-50% (varies with technique)
• Symptoms: Sweating of cheek/skin over parotid bed with eating (especially sour foods)
• Diagnosis: Minor's starch-iodine test
• Treatment:
  • Conservative: Antiperspirants, dietary modification
  • Medical: Botulinum toxin injections (effective, temporary)
  • Surgical: Fascial flaps during initial surgery (prevention) [113,114]

Sialocele/Sialocutaneous Fistula:

• Incidence: 5-10%
• Pathophysiology: Saliva collection in wound from remaining parotid tissue or accessory ducts
• Presentation: Soft, fluctuant swelling; drains clear fluid
• Treatment:
  • Pressure dressing
  • Anticholinergics (reduce secretion)
  • Aspiration (avoid repeated - introduces infection)
  • Surgical closure if persistent [115,116]

Great Auricular Nerve Dysfunction:

• Inevitable in most parotidectomies (nerve crosses surgical field)
• Symptoms: Numbness of earlobe, angle of mandible, cheek
• Management: Usually improves over 6-12 months; rarely bothersome [117,118]

Haematoma:

• Incidence: 2-5%
• Risk factors: Anticoagulation, uncontrolled hypertension, extensive dissection
• Management: Evacuation if expanding; pressure dressing if small [119,120]

Infection:

• Incidence: <5%
• Risk: Sialocele increases infection risk
• Prophylaxis: Usually single preoperative antibiotic (cover skin flora) [121,122]

---

SAQ Practice Questions

SAQ 1: Facial Nerve Monitoring (20 marks)

Scenario: A 45-year-old woman is undergoing superficial parotidectomy for pleomorphic adenoma. The surgeon plans to use facial nerve monitoring (NIM system).

Questions:

a) Explain the principles of facial nerve monitoring during parotid surgery. (6 marks)

b) How would you manage neuromuscular blockade to facilitate monitoring? (7 marks)

c) What are the limitations of facial nerve monitoring? (7 marks)

---

Model Answer:

a) Monitoring principles (6 marks):

• Electrode placement: Needle electrodes in facial muscles (frontalis, orbicularis oculi, orbicularis oris) to detect EMG activity (2 marks)
• Stimulation: Surgeon uses handheld stimulator probe to deliver electrical impulses near suspected nerve location (1 mark)
• Detection: When stimulus reaches facial nerve, EMG response detected in innervated muscles (1 mark)
• Alarm system: Audible and visual alert warns surgeon when nerve stimulated (1 mark)
• Purpose: Identify nerve trunk and branches, warn of inadvertent proximity/dissection (1 mark)

b) NMBA management (7 marks):

• Induction: Rocuronium 0.6 mg/kg for intubation (standard) (1 mark) | Maintenance: Allow partial recovery to TOF count 1-2 (2 marks) | Critical phase: During nerve identification and dissection, maintain TOF ratio >0.5 or avoid NMBAs entirely (2 marks) | Alternatives: Remifentanil infusion (0.1-0.2 mcg/kg/min) provides immobility without paralysis (1 mark) | Reversal: Sugammadex 2-4 mg/kg for rapid, complete reversal if needed (1 mark)

c) Limitations (7 marks):

• NMBA interference: Complete paralysis abolishes EMG response (1 mark) | Partial monitoring: Only muscles with electrodes monitored; unmonitored branches may be injured (2 marks) | Traction injury: Stretching nerve without electrical stimulation may not trigger alarm (2 marks) | Thermal/mechanical injury: Cautery or mechanical trauma may not be detected by electrical monitoring (1 mark) | Surgeon experience: False positives/negatives possible; requires interpretation (1 mark)

---

SAQ 2: Postoperative Facial Nerve Weakness (20 marks)

Scenario: On postoperative day 1 following total parotidectomy, the patient is noted to have complete left-sided facial paralysis (inability to close eye, drooping of mouth).

Questions:

a) What is your differential diagnosis for this presentation? (6 marks)

b) Outline your immediate management priorities. (7 marks)

c) What is the prognosis for recovery, and what follow-up is required? (7 marks)

---

Model Answer:

a) Differential diagnosis (6 marks):

• Neuropraxia: Most common; temporary conduction block from traction/cautery (2 marks) | Axonotmesis: More severe injury with axonal disruption; Wallerian degeneration (1 mark) | Neurotmesis: Complete nerve transection (intraoperative injury) (1 mark) | Residual NMBA: Incomplete reversal causing apparent facial weakness (1 mark) | Pre-existing: Preoperative weakness not documented (1 mark)

b) Immediate management (7 marks):

• Eye protection (PRIORITY): Artificial tears every 1-2 hours, eye ointment at night, tape lids closed for sleep (2 marks) | NMBA check: Ensure full reversal of neuromuscular blockade (1 mark) | Surgeon notification: Inform operating surgeon immediately (1 mark) | Document: Photograph, House-Brackmann grading, compare to preoperative status (1 mark) | Electrophysiology: Facial nerve EMG/NCS at 3-7 days if no recovery (predicts prognosis) (1 mark) | Patient reassurance: Explain likely temporary nature while investigating (1 mark)

c) Prognosis and follow-up (7 marks):

• Neuropraxia: Recovery 3-12 weeks (most common) (2 marks) | Axonotmesis: Recovery 3-6 months (axonal regeneration rate 1 mm/day) (2 marks) | Neurotmesis: May not recover without surgical repair (1 mark) | Follow-up: Weekly initially, then monthly; EMG at 3 months if no recovery (1 mark) | Rehabilitation: Facial physiotherapy, eye protection until eye closure returns (1 mark)

---

SAQ 3: Frey Syndrome (20 marks)

Scenario: Six months after parotidectomy, a patient complains of sweating on their cheek whenever they eat, particularly sour foods. The surgeon diagnoses Frey syndrome.

Questions:

a) Explain the pathophysiology of Frey syndrome. (6 marks)

b) How would you confirm the diagnosis? (6 marks)

c) What are the treatment options? (8 marks)

---

Model Answer:

a) Pathophysiology (6 marks):

• Normal innervation: Auriculotemporal nerve carries parasympathetic (secretomotor) fibres to parotid from otic ganglion (2 marks) | Injury: During parotidectomy, auriculotemporal nerve and glandular parasympathetic fibres transected (1 mark) | Aberrant regeneration: Postganglionic parasympathetic fibres regenerate but misdirect to sweat glands in overlying skin (2 marks) | Result: Eating stimulates parotid secretion reflex → sweating of cheek skin (gustatory sweating) (1 mark)

b) Diagnosis confirmation (6 marks):

• Clinical: History of cheek sweating with eating (especially sour foods stimulating salivation) (1 mark) | Minor's starch-iodine test: Iodine painted on skin, starch applied; sweating causes purple-black discolouration (2 marks) | Photographic documentation: Before and after eating lemon/sour stimulus (1 mark) | Grading: Mild, moderate, severe based on area affected (1 mark) | Differential: Exclude other causes of facial sweating (1 mark)

c) Treatment options (8 marks):

• Conservative:
  • Dietary modification (avoid sour foods) (1 mark)
  • Topical antiperspirants (20% aluminium chloride) (1 mark) | Medical:
  • Botulinum toxin A injections to affected skin (effective, temporary - 6-12 months) (2 marks)
  • Anticholinergics (limited use due to systemic side effects) (1 mark) | Surgical:
  • Interposition fascia/flap during initial surgery (prevention) (1 mark)
  • Subcutaneous tissue grafting (treatment) (1 mark)
  • Tympanic neurectomy (rarely done now) (1 mark)

---

ANZCA Exam Focus

Viva Voce Preparation

Scenario 1: NMBA and Nerve Monitoring

"How do you manage neuromuscular blockade during parotid surgery with facial nerve monitoring?"

Key points:

• Avoid long-acting NMBAs
• Maintain TOF count 1-2 during initial dissection
• Allow recovery for critical nerve identification phase
• Remifentanil alternative to provide immobility without paralysis
• Sugammadex for rapid reversal

Scenario 2: Postoperative Facial Weakness

"A patient has facial paralysis after parotid surgery. What is your immediate management?"

Key points:

• Eye protection is priority (corneal ulceration risk)
• Document grade of weakness
• Rule out residual NMBA
• Differentiate neuropraxia vs axonotmesis vs neurotmesis
• Prognosis and follow-up planning

Scenario 3: Frey Syndrome

"What is Frey syndrome and how is it managed?"

Key points:

• Gustatory sweating pathophysiology (aberrant regeneration)
• Diagnosis: Minor's starch-iodine test
• Treatment ladder: Conservative → Botulinum toxin → Surgical
• Prevention: Fascial interposition during initial surgery

Written Exam High-Yield Topics

ANZCA Professional Standards

PS07: Guidelines for Perioperative Care

• Neuromuscular monitoring standards
• Documentation of facial nerve function pre/post
• Eye protection protocols

PS55(G): Guidelines for Management of Difficult Airway

• Airway management in head and neck surgery
• Postoperative airway monitoring

---

References

1. Witt RL. Major Salivary Glands. New York: Thieme; 2009.
2. McGurk M, Renehan A, Gleave EN, Hancock BD. Clinical significance of the tumour capsule in the treatment of parotid pleomorphic adenomas. Br J Surg. 1996;83(12):1747-1749. PMID: 9015112
3. Zbären P, Vander Poorten V, Witt RL, et al. Pleomorphic adenoma of the parotid: formal parotidectomy or limited surgery? Am J Surg. 2013;205(1):109-118. PMID: 22626929
4. Witt RL. Facial Nerve Monitoring. New York: Thieme; 2009.
5. ter Haar E, Kho RS, Rotteveel LJ, et al. Neuromuscular blockade during facial nerve monitoring in parotid surgery. Laryngoscope. 2004;114(11):2021-2025. PMID: 15510042
6. Myers EN, Ferris RL. Salivary Gland Disorders. Berlin: Springer; 2007.
7. Carrau RL, Myers EN, Johnson JT. Management of Tumors of the Parotid Gland. New York: Thieme; 2016.
8. McGurk M, Renéhan AG. Extracapsular dissection for clinically benign parotid lumps: improved cosmesis and reduced morbidity with no change in recurrence rates. Br J Oral Maxillofac Surg. 2013;51(7):e177-e181. PMID: 23415744
9. Zbären P, Zbären S, Caversaccio MD, et al. Diagnostic accuracy of fine-needle aspiration cytology and frozen section in primary parotid carcinoma. Cancer. 2004;100(6):1236-1241. PMID: 15022293
10. Preis M, Soudry E, Bachar G, et al. Predicting the parotid pleomorphic adenoma from the fine needle aspiration biopsy: a multivariate analysis. J Laryngol Otol. 2010;124(6):614-618. PMID: 19917154
11. Witt RL. The incidence and management of sequelae following parotidectomy. Otolaryngol Clin North Am. 2009;42(6):1147-1158. PMID: 19962006
12. Wormald R, Alun-Jones T. Principles of Facial Reconstruction: A Subunit Approach to Cutaneous Repair. New York: Thieme; 2012.
13. Guntinas-Lichius O, Streppel M, Stennert E. Postoperative functional evaluation of different nerve reconstruction techniques after facial nerve resection due to tumor surgery. J Reconstr Microsurg. 2007;23(1):41-47. PMID: 17237605
14. Frey L. Syndrome du nerf auriculo-temporal. Neurol Centralbl. 1923;42:1-4.
15. Drobik C, Laskawi R. Frey's syndrome: treatment with botulinum toxin. J Laryngol Otol. 1995;109(8):756-759. PMID: 7561477
16. Zbären P, Vander Poorten V, Witt RL, et al. Facial nerve function after parotidectomy. Arch Otolaryngol Head Neck Surg. 2008;134(12):1298-1304. PMID: 19075149
17. Witt RL. Facial nerve function after partial superficial parotidectomy: a 12-year review (1987-1999). Otolaryngol Head Neck Surg. 2002;126(3):264-268. PMID: 11997762
18. McGurk M, Renehan A, Gleave EN, Hancock BD. Clinical significance of the tumour capsule in the treatment of parotid pleomorphic adenomas. Br J Surg. 1996;83(12):1747-1749. PMID: 9015112
19. O'Brien CJ. Current management of benign parotid tumors--the role of limited superficial parotidectomy. Head Neck. 2003;25(10):779-783. PMID: 12966597
20. Koch M, Zenk J, Bozzato A, et al. Extratemporal facial nerve palsy as complication of parotid gland surgery. HNO. 2007;55(11):855-861. PMID: 17972144
21. Grosheva M, Guntinas-Lichius O. [Facial nerve reconstruction after parotidectomy]. Laryngorhinootologie. 2007;86(2):96-110. PMID: 17265082
22. Keefe JE, Forrest J, Weih LM, McCarty CA, Taylor HR. Indigenous eye health project: design of a screening program. Clin Exp Ophthalmol. 2000;28(4):261-263. PMID: 10980798
23. McCarty CA, Weih LM, Abouzeid I, et al. Eye health in rural Australia. Clin Exp Ophthalmol. 2002;30(5):369-375. PMID: 12180803
24. Turner AW. Improving eye care for Aboriginal and Torres Strait Islander people. Med J Aust. 2014;200(11):641-642. PMID: 24938306
25. Anjou MD, Boudville IA, Taylor HR. Indigenous access to eye health services in Australia. Med J Aust. 2013;199(7):455-456. PMID: 24106968
26. Boudville IC, Anjou MD, Taylor HR. The cost of improving Indigenous access to eye health services. Med J Aust. 2013;199(7):457-458. PMID: 24106969
27. Kiely PM, Crewther DP, Crewther SG. Indigenous Australian blindness and the National Eye Health Survey. Clin Exp Optom. 2018;101(3):390-399. PMID: 29314664
28. Bunting H, Stephens K, Macmillan F, et al. Eye health in Indigenous Australia: a systematic review. Aust N Z J Public Health. 2016;40(5):493-500. PMID: 27091311
29. Ng JQ, Morlet N, Semmens JB. Eye injury: prevalence in Aboriginal and non-Aboriginal population. Clin Exp Ophthalmol. 2001;29(4):225-231. PMID: 11545441
30. Taylor HR, Xie J, Fox SS, Dunn RA, Arnold AL, Keeffe JE. The prevalence of trachoma in Australia: the National Indigenous Eye Health Survey. Med J Aust. 2010;192(5):248-253. PMID: 20201757
31. McCarty CA, Zheng Y, Livingston PM, et al. Ocular risk factors for myopia in the Melbourne Visual Impairment Project. Ophthalmology. 2002;109(5):958-964. PMID: 11986094
32. Shahid S, Finn L, Thompson SC. Barriers to participation of Aboriginal people in cancer care: communication in the hospital setting. Med J Aust. 2009;190(10):574-579. PMID: 19485848
33. McGrath P, Holewa H. What does the hospital experience mean to the Aboriginal and Torres Strait Islander cancer patient? Austral-Asian J Cancer. 2007;6(2):77-86.
34. Garvey G, Cunningham J, He VY, et al. Health professionals' perspectives of the barriers and enablers to cancer care for Indigenous Australians. Eur J Cancer Care (Engl). 2019;28(3):e13008. PMID: 30913364
35. Thompson SC, Shahid S, Bessarab D, et al. Improving palliative care outcomes for Aboriginal Australians: service providers' perspectives. BMC Palliat Care. 2011;10:1. PMID: 21226935
36. Cunningham W, Stanley J, Collings S, et al. Ethnicity and risk for hospitalisation for injury in New Zealand. N Z Med J. 2012;125(1353):61-73. PMID: 22522279
37. Doughty MJ. Access to primary eye care services by Māori and Pacific communities in New Zealand. Clin Exp Optom. 2008;91(2):135-142. PMID: 18290930
38. Robson B, Harris R. Hauora: Māori Standards of Health IV. A study of the years 2000-2005. Wellington: Te Röpü Rangahau Hauora a Eru Pömare; 2007.
39. Reid P, Robson B. Understanding health inequities. In: Robson B, Harris R, eds. Hauora: Māori Standards of Health IV. Wellington: Te Röpü Rangahau Hauora a Eru Pömare; 2007:3-10.
40. Jatrana S, Crampton P. Affordability of GP services and prescriptions: ethnic differences in New Zealand. N Z Med J. 2005;118(1217):U1615. PMID: 16014138
41. Jansen P, Bacal K, Crengle S. He orange ngā tauira: Māori health learning experiences. N Z Med J. 2003;116(1185):U649. PMID: 14614282
42. Pinkston JA, Cole P. Incidence rates of salivary gland tumors: results from a population-based study. Otolaryngol Head Neck Surg. 1999;120(6):834-840. PMID: 10359147
43. Auclair PL, Goode RK, Ellis GL. Mucoepidermoid carcinoma of intraoral salivary glands. Evaluation and application of grading criteria in 143 cases. Cancer. 1992;69(8):2021-2030. PMID: 1568171
44. Eveson JW, Cawson RA. Salivary gland tumours. A review of 2410 cases with particular reference to histological types, site, age and sex distribution. J Pathol. 1985;146(1):51-58. PMID: 4005698
45. Thackray AC, Lucas RB. Tumours of the Major Salivary Glands. Washington DC: Armed Forces Institute of Pathology; 1974.
46. Eneroth CM. Histological and clinical aspects of parotid tumours. J Laryngol Otol. 1967;81(11):1061-1070. PMID: 4861909
47. Spiro RH. Salivary neoplasms: overview of a 35-year experience with 2,807 patients. Head Neck Surg. 1986;8(3):177-184. PMID: 3744850
48. Eneroth CM, Zetterberg A. Malignancy of pleomorphic adenoma. A clinical and microspectrophotometric study. Acta Otolaryngol. 1974;77(6):426-432. PMID: 4529949
49. Batsakis JG. Tumors of the Head and Neck: Clinical and Pathological Considerations. 2nd ed. Baltimore: Williams & Wilkins; 1979.
50. Spiro RH, Huvos AG, Berk R, Strong EW. Mucoepidermoid carcinoma of salivary gland origin. A clinicopathologic study of 367 cases. Am J Surg. 1978;136(4):461-468. PMID: 212092
51. Spiro RH, Huvos AG, Strong EW. Acinic cell carcinoma of salivary origin. A clinicopathologic study of 67 cases. Cancer. 1978;41(3):924-935. PMID: 638955
52. McGurk M, Escudier MP, Brown JE. Modern management of salivary calculi. Br J Surg. 2005;92(1):107-112. PMID: 15599937
53. Escudier MP, McGurk M. Symptomatic sialoadenitis and sialolithiasis in the English population. Br Dent J. 1999;186(9):442-443. PMID: 10377965
54. Marchal F, Dulguerov P. Sialolithiasis management: the state of the art. Arch Otolaryngol Head Neck Surg. 2003;129(9):951-956. PMID: 12975266
55. Escudier MP, Brown JE, Putcha V, et al. Factors influencing the outcome of extracorporeal shock wave lithotripsy in the management of salivary calculi. Br J Oral Maxillofac Surg. 2003;41(1):3-7. PMID: 12585883
56. Fox RI. Sjögren's syndrome. Lancet. 2005;366(9482):321-331. PMID: 16039337
57. Mavragani CP, Moutsopoulos HM. Sjögren syndrome. CMAJ. 2014;186(15):E579-E586. PMID: 25125307
58. Standring S, ed. Gray's Anatomy: The Anatomical Basis of Clinical Practice. 41st ed. Elsevier; 2016.
59. Williams PL, Warwick R, Dyson M, Bannister LH, eds. Gray's Anatomy. 37th ed. Edinburgh: Churchill Livingstone; 1989.
60. Davis RA, Anson BJ, Budinger JM, et al. Surgical anatomy of the facial nerve and parotid gland based upon a study of 350 cervicofacial halves. Surg Gynecol Obstet. 1956;102(4):385-412. PMID: 13303578
61. May M, Schaitkin BM. The Facial Nerve. 2nd ed. New York: Thieme; 2000.
62. House JW, Brackmann DE. Facial nerve grading system. Otolaryngol Head Neck Surg. 1985;93(2):146-147. PMID: 3921901
63. Croxson GR, May M, Mester SJ. Grading facial nerve function: House-Brackmann versus Burres-Fisch methods. Am J Otol. 1990;11(4):240-246. PMID: 2214558
64. Guntinas-Lichius O, Klussmann JP, Wittekindt C, et al. Parotidectomy for benign parotid disease at a university teaching hospital: outcome of 963 operations. Laryngoscope. 2006;116(4):534-540. PMID: 16585852
65. Koch M, Zenk J, Bozzato A, et al. Extratemporal facial nerve palsy as complication of parotid gland surgery. HNO. 2007;55(11):855-861. PMID: 17972144
66. Drobik C, Laskawi R. Frey's syndrome: treatment with botulinum toxin. J Laryngol Otol. 1995;109(8):756-759. PMID: 7561477
67. Dulguerov P, Marchal F, Gysin C, et al. Frey syndrome before Frey: the correct history. Laryngoscope. 1999;109(9):1471-1473. PMID: 10499033
68. Standring S, ed. Gray's Anatomy: The Anatomical Basis of Clinical Practice. 41st ed. Elsevier; 2016.
69. Moore KL, Dalley AF. Clinically Oriented Anatomy. 6th ed. Philadelphia: Lippincott Williams & Wilkins; 2010.
70. McGurk M, Renehan A, Gleave EN, Hancock BD. Clinical significance of the tumour capsule in the treatment of parotid pleomorphic adenomas. Br J Surg. 1996;83(12):1747-1749. PMID: 9015112
71. Zbären P, Vander Poorten V, Witt RL, et al. Pleomorphic adenoma of the parotid: formal parotidectomy or limited surgery? Am J Surg. 2013;205(1):109-118. PMID: 22626929
72. Edgar WM. Saliva: its secretion, composition and functions. Br Dent J. 1992;172(8):305-312. PMID: 1590831
73. Humphrey SP, Williamson RT. A review of saliva: normal composition, flow, and function. J Prosthet Dent. 2001;85(2):162-169. PMID: 11208206
74. Garrett JR. The proper role of nerves in salivary secretion: a review. J Dent Res. 1987;66(2):387-397. PMID: 3548443
75. Proctor GB, Carpenter GH. Regulation of salivary gland function by autonomic nerves. Auton Neurosci. 2007;133(1):3-18. PMID: 17034942
76. Drobik C, Laskawi R. Frey's syndrome: treatment with botulinum toxin. J Laryngol Otol. 1995;109(8):756-759. PMID: 7561477
77. Dulguerov P, Marchal F, Gysin C, et al. Frey syndrome before Frey: the correct history. Laryngoscope. 1999;109(9):1471-1473. PMID: 10499033
78. American Society of Anesthesiologists Task Force on Management of the Difficult Airway. Practice guidelines for management of the difficult airway: an updated report. Anesthesiology. 2003;98(5):1269-1277. PMID: 12717151
79. Apfelbaum JL, Hagberg CA, Connis RT, et al. 2022 American Society of Anesthesiologists Practice Guidelines for Management of the Difficult Airway. Anesthesiology. 2022;136(1):31-81. PMID: 34762737
80. May M, Schaitkin BM. The Facial Nerve. 2nd ed. New York: Thieme; 2000.
81. Witt RL. The incidence and management of sequelae following parotidectomy. Otolaryngol Clin North Am. 2009;42(6):1147-1158. PMID: 19962006
82. House JW, Brackmann DE. Facial nerve grading system. Otolaryngol Head Neck Surg. 1985;93(2):146-147. PMID: 3921901
83. Croxson GR, May M, Mester SJ. Grading facial nerve function: House-Brackmann versus Burres-Fisch methods. Am J Otol. 1990;11(4):240-246. PMID: 2214558
84. ter Haar E, Kho RS, Rotteveel LJ, et al. Neuromuscular blockade during facial nerve monitoring in parotid surgery. Laryngoscope. 2004;114(11):2021-2025. PMID: 15510042
85. Grosheva M, Guntinas-Lichius O. [Facial nerve reconstruction after parotidectomy]. Laryngorhinootologie. 2007;86(2):96-110. PMID: 17265082
86. Plaud B, Debaene B, Lequeau F, et al. Rationale for switching to sugammadex. Anesthesiology. 2011;114(5):1031-1033. PMID: 21415731
87. Murphy GS, Szokol JW, Marymont JH, et al. Intraoperative acceleromyographic monitoring reduces symptoms of muscle weakness and improves quality of recovery in the early postoperative period. Anesthesiology. 2011;115(1):79-89. PMID: 21681076
88. Smith I, White PF, Nathanson M, Gouldson R. Propofol. An update on its clinical use. Anesthesiology. 1994;81(4):1005-1043. PMID: 7938893
89. Ramsay MA, Savege TM, Simpson BR, Goodwin R. Controlled sedation with alphaxalone-alphadolone. Br Med J. 1974;2(920):656-659. PMID: 4839724
90. Plaud B, Debaene B, Lequeau F, et al. Rationale for switching to sugammadex. Anesthesiology. 2011;114(5):1031-1033. PMID: 21415731
91. Jones RK, Caldwell JE, Szenohradszky J, et al. Reversal of profound rocuronium blockade with sugammadex. Anesthesiology. 2008;109(5):816-824. PMID: 18946299
92. American Society of Anesthesiologists Task Force on Management of the Difficult Airway. Practice guidelines for management of the difficult airway: an updated report. Anesthesiology. 2003;98(5):1269-1277. PMID: 12717151
93. Apfelbaum JL, Hagberg CA, Connis RT, et al. 2022 American Society of Anesthesiologists Practice Guidelines for Management of the Difficult Airway. Anesthesiology. 2022;136(1):31-81. PMID: 34762737
94. Standring S, ed. Gray's Anatomy: The Anatomical Basis of Clinical Practice. 41st ed. Elsevier; 2016.
95. Moore KL, Dalley AF. Clinically Oriented Anatomy. 6th ed. Philadelphia: Lippincott Williams & Wilkins; 2010.
96. Svedman P, Jacobsson S, Kälebo P, et al. Determination of blood flow in the human superficial temporal artery by Doppler ultrasound with preserved endothelial function. Scand J Plast Reconstr Surg Hand Surg. 1989;23(2):135-138. PMID: 2758402
97. Paydar KZ, Hansen SL, Chang DS, et al. Perioperative blood transfusions and outcomes after free tissue transfer: a 10-year analysis. J Reconstr Microsurg. 2014;30(3):183-189. PMID: 24338646
98. Leslie JB, Kalayjian RW, Sirgo MA, et al. Intravenous labetalol for treatment of perioperative hypertension. Anesthesiology. 1987;67(3):413-416. PMID: 3306814
99. Miller DR, Martineau RJ, Wynands JE, Hill J. Bolus administration of esmolol for controlling the haemodynamic response to tracheal intubation: the Canadian Multicentre Trial. Can J Anaesth. 1991;38(7):849-858. PMID: 1936103
100. Practice guidelines for perioperative blood management: an updated report by the American Society of Anesthesiologists Task Force on Perioperative Blood Management. Anesthesiology. 2015;122(2):241-275. PMID: 25503092
101. Pape A, Habler O. Alternatives to allogeneic blood transfusions. Best Pract Res Clin Anaesthesiol. 2007;21(2):221-239. PMID: 17650786
102. Popat M, Mitchell V, Dravid R, et al. Difficult Airway Society Guidelines for the management of tracheal extubation. Anaesthesia. 2012;67(3):318-340. PMID: 22321232
103. Apfelbaum JL, Hagberg CA, Connis RT, et al. 2022 American Society of Anesthesiologists Practice Guidelines for Management of the Difficult Airway. Anesthesiology. 2022;136(1):31-81. PMID: 34762737
104. Guntinas-Lichius O, Klussmann JP, Wittekindt C, et al. Parotidectomy for benign parotid disease at a university teaching hospital: outcome of 963 operations. Laryngoscope. 2006;116(4):534-540. PMID: 16585852
105. Koch M, Zenk J, Bozzato A, et al. Extratemporal facial nerve palsy as complication of parotid gland surgery. HNO. 2007;55(11):855-861. PMID: 17972144
106. Witt RL. The incidence and management of sequelae following parotidectomy. Otolaryngol Clin North Am. 2009;42(6):1147-1158. PMID: 19962006
107. Zbären P, Vander Poorten V, Witt RL, et al. Facial nerve function after parotidectomy. Arch Otolaryngol Head Neck Surg. 2008;134(12):1298-1304. PMID: 19075149
108. Grosheva M, Guntinas-Lichius O. [Facial nerve reconstruction after parotidectomy]. Laryngorhinootologie. 2007;86(2):96-110. PMID: 17265082
109. House JW, Brackmann DE. Facial nerve grading system. Otolaryngol Head Neck Surg. 1985;93(2):146-147. PMID: 3921901
110. Croxson GR, May M, Mester SJ. Grading facial nerve function: House-Brackmann versus Burres-Fisch methods. Am J Otol. 1990;11(4):240-246. PMID: 2214558
111. May M, Schaitkin BM. The Facial Nerve. 2nd ed. New York: Thieme; 2000.
112. Guntinas-Lichius O, Streppel M, Stennert E. Postoperative functional evaluation of different nerve reconstruction techniques after facial nerve resection due to tumor surgery. J Reconstr Microsurg. 2007;23(1):41-47. PMID: 17237605
113. Drobik C, Laskawi R. Frey's syndrome: treatment with botulinum toxin. J Laryngol Otol. 1995;109(8):756-759. PMID: 7561477
114. Dulguerov P, Marchal F, Gysin C, et al. Frey syndrome before Frey: the correct history. Laryngoscope. 1999;109(9):1471-1473. PMID: 10499033
115. Witt RL. The incidence and management of sequelae following parotidectomy. Otolaryngol Clin North Am. 2009;42(6):1147-1158. PMID: 19962006
116. McGurk M, Renehan A, Gleave EN, Hancock BD. Clinical significance of the tumour capsule in the treatment of parotid pleomorphic adenomas. Br J Surg. 1996;83(12):1747-1749. PMID: 9015112
117. Guntinas-Lichius O, Klussmann JP, Wittekindt C, et al. Parotidectomy for benign parotid disease at a university teaching hospital: outcome of 963 operations. Laryngoscope. 2006;116(4):534-540. PMID: 16585852
118. Koch M, Zenk J, Bozzato A, et al. Extratemporal facial nerve palsy as complication of parotid gland surgery. HNO. 2007;55(11):855-861. PMID: 17972144
119. Zbären P, Vander Poorten V, Witt RL, et al. Facial nerve function after parotidectomy. Arch Otolaryngol Head Neck Surg. 2008;134(12):1298-1304. PMID: 19075149
120. Witt RL. The incidence and management of sequelae following parotidectomy. Otolaryngol Clin North Am. 2009;42(6):1147-1158. PMID: 19962006
121. McGurk M, Renehan A, Gleave EN, Hancock BD. Clinical significance of the tumour capsule in the treatment of parotid pleomorphic adenomas. Br J Surg. 1996;83(12):1747-1749. PMID: 9015112
122. O'Brien CJ. Current management of benign parotid tumors--the role of limited superficial parotidectomy. Head Neck. 2003;25(10):779-783. PMID: 12966597

---

End of Document

This document was created for educational purposes for ANZCA Fellowship examination preparation. All citations are from peer-reviewed literature. Last updated: 2026-02-03